The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3, double-blind ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the ...
An Interim analysis of 18 patients, completing 24/25 weeks of treatment in a phase 2 study in complement-naïve PNH patients demonstrates that KP104 is safe, well-tolerated, and has successfully met ...
SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback